• 1
    Moake JL. Thrombotic microangiopathies. New Engl J Med 2002; 347: 589600.
  • 2
    Török TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States – analysis of national mortality data, 1968–1991. Am J Hematol 1995; 50: 8490.
  • 3
    Sington JD, Cottrell BJ. Analysis of the sensitivity of death certificates in 440 hospital deaths: a comparison with necropsy findings. J Clin Pathol 2002; 55: 499502.
  • 4
    Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 13959.
  • 5
    Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. New Engl J Med 1991; 325: 3937.
  • 6
    Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, Walker AM. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 2004; 15: 20815.
  • 7
    Vesely SK, George JN, Lammle B, Studt J-D, Alberio L, El-Harake MA, Raskob GE. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 101: 608.
  • 8
    George JN, Vesely SK, Terrell DR. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 607.
  • 9
    George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 12239.
  • 10
    US Census Bureau. Census 2000 Summary File 2; using American Fact Finder. Available at:, accessed on August 27, 2004.
  • 11
    Clark WF, Garg AX, Blake PG, Rock GA, Heidenhwim AP, Sackett DL. Effect of awareness of a randomized controlled trial on use of experimental therapy. JAMA 2003; 290: 13515.
  • 12
    Greenland S, Rothman KJ. Introduction to stratified analysis. In: RothmanKJ, GreenlandS, eds. Modern Epidemiology, 2nd edn. Philadelphia, USA: Lippincott, Williams, and Wilkins, 1998.
  • 13
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New Engl J Med 1998; 339: 157884.
  • 14
    Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. von Willebrand factor-cleaving protease (ADAMTS-13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 7103.
  • 15
    Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma J-P, Moake J, Rick ME, Studt J-D, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 16019.
  • 16
    Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong JF, Cruz MA. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004; 2: 48591.
  • 17
    Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS-13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 40439.
  • 18
    Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 43754.
  • 19
    George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003; 10: 33944.
  • 20
    Conlon PJ, Howell DN, Macik G, Kovalik EC, Smith SR. The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrol Dial Transplant 1995; 10: 118993.
  • 21
    Elkins SL, Wilson PP, Files JC, Morrison FS. Thrombotic thrombocytopenic purpura: evolution across 15 years. J Clin Apheresis 1996; 11: 1735.
  • 22
    McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995; 38: 126076.
  • 23
    Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003; 1: 21917.